ChemicalBook
Chinese Japanese Germany Korea

AHU-377

Pharmacologic action Novartis’ New Angiomyocardiac LCZ696 Market analysis
AHU-377
AHU-377 structure
CAS No.
149709-62-6
Chemical Name:
AHU-377
Synonyms
AHU-77;LCZ697;AHU-377;Sacubitril API;LCZ-696-007-2S4R;Sacubtril(LCZ696);LCZ-696 Impurity 3;AHU-377(Sacubitril);Sacubitril(AHU-377);Sacubitril Related Compound 1
CBNumber:
CB62627304
Molecular Formula:
C24H29NO5
Formula Weight:
411.49
MOL File:
149709-62-6.mol

AHU-377 Properties

SAFETY

AHU-377 price

Manufacturer Product number Product description CAS number Packaging Price Updated Buy

AHU-377 Chemical Properties,Uses,Production

Pharmacologic action

AHU377 and angiotensin IIAT1 receptor antagonist valsartan at a molar ratio of 1: 1 compose LCZ696. LCZ696 was a dual inhibitor of angiotensin II (AT2) receptor and enkephalinase (Neprilysin) receptor. And with its better antihypertensive efficacy than standard antihypertensive drugs, it is a new drug for the treatment of heart failure.
AHU377 is a prodrug that converts the active form of the enzyme cleavage LBQ657 ethyl ester. So far its efficacy and safety in milestone phase III surpass the clinical standard drug enalapril.
In a clinical trial of the drug, 100 to 400 mg of combined drugs, 80 to 320 mg of valsartan, 200 mg of neprilysin inhibition or placebo were given to the patients in the double-blind trial of phase two with mild to moderate hypertension. The combined drugs are more effective and better tolerated with no vascular edema report than solely applied valsartan or other drugs. LCZ696 shows sustainable treatment benefits in the early treatment:
(1) a 20% reduction in the risk of death from cardiovascular disease (p = 0.00004).
(2) hospitalization for heart failure was reduced by 21% (p = 0.00004).
(3) all-cause mortality was reduced by 16% (p = 0.0005).
(4) The overall risk is reduced by 20% according to the composite measure of the primary endpoint of hospitalization for cardiovascular death or heart failure (p = 0.0000002).

Novartis’ New Angiomyocardiac LCZ696

According to a recent study published by Novartis, LCZ696, a cardiovascular drug being developed by the company, will become a new hope for the company. The current study shows that this drug functions well in the remission of cardiovascular necrosis and other symptoms caused by heart disease.
LCZ696 is a combination of Novartis Diovan and AHU-377. Some analysts have spoken highly of the drug and estimated that it might be submitted to the FDA as early as next year. Once confirmed in the audit it will mark another great step forward of Novartis in the field of cardiovascular drugs.
Although it showed high expectations to LCZ696, Novartis still has a long way to go, given the setbacks of its serelaxin in the FDA and the European Medicines Administration.
The news came straight from Basel as investigators around the world were wrapping up the big scientific meeting of the American College of Cardiology.

Market analysis

In the field of research and development of drugs, most of the success of the new drugs in phase II will always lead to a series of competitor projects. The LCZ696 performs so prominently that the industry was shocked. It is predicted that few cardiovascular drugs will be qualified to compete with the LCZ696 in the next few years. Some analysts predict that the LCZ696 sales will peak at $ 8 billion, while Deutsche Bank analysts expect the drug to peak at $ 6 billion, given LCZ696's superior performance in reducing cardiovascular risk. Although the data are slightly different, there is no doubt that, LCZ696 will become a super star to lead the cardiovascular treatment to step into a new era.

AHU-377 Preparation Products And Raw materials

Raw materials

Preparation Products


AHU-377 Suppliers

Global( 136)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 sales@capotchem.com China 19918 60
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 21990 58
Shanghai Bojing Chemical Co.,Ltd.
+86-21-37122233
+86-21-37127788 Candy@bj-chem.com CHINA 495 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20680 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070;product@chemlin.com.cn
product@chemlin.com.cn CHINA 3015 60
Biochempartner
0086-13720134139
candy@biochempartner.com CHINA 956 58
Nanjing Dolon Biotechnology Co.,Ltd.
18905173768
sales@dolonchem.com CHINA 2972 58
Chemwill Asia Co.,Ltd.
86-21-51086038
86-21-51861608 chemwill_asia@126.com;sales@chemwill.com;chemwill@hotmail.com;chemwill@gmail.com CHINA 24001 58
Hubei Jusheng Technology Co.,Ltd.
86-188-71490254
peter@hubeijusheng.com CHINA 20095 58
Casorganics US Corp
+17326109938
sales@casorganics.com CHINA 141 58

View Lastest Price from AHU-377 manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-07-25 AHU-377
149709-62-6
US $100.00 / KG 100G 98% 200KG career henan chemical co

149709-62-6(AHU-377)Related Search:


  • LCZ-696-007-2S4R
  • 4-《(2S,4R)-I-([I,I'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amin
  • valsartan/sacubitril Impurity 1
  • AHU-377
  • LCZ696(valsartan + sacubitril) impurity 4
  • AHU-377(Sacubitril)
  • 4-(((2S,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-Methyl-5-oxopentan-2-yl)aMino)-4-oxobutanoic acid
  • 4-(((2R,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-Methyl-5-oxopentan-2-yl)aMino)-4-oxobutanoic acid
  • (2R,4S)-5-(Biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic acid ethyl ester
  • (2R,4S)-5-([1,1'-Biphenyl]-4-yl)-4-(3-carboxypropanamido)-2-methylpentanoic acid
  • 4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid
  • 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid
  • 149709-62-6
  • LCZ696
  • intermediates
  • Sacubitril
  • AHU-77
  • Sacubitril(AHU-377)
  • (2R,4S)-5-([1,1'-Biphenyl]-4-yl)-4-(3-carboxypropanamido)-2-methylpentanoic acid (Sacubitril , AHU-377)
  • LCZ697
  • 4-(((2S,4R)-1-([1,1'-Biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoic a
  • Entresto( sacubitril+ valsartan)
  • LCZ-696 Impurity 3
  • (2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic Acid Ethyl Ester
  • Sacubitril Related Compound 1
  • [1,1'-Biphenyl]-4-pentanoic acid, γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl-, α-ethyl ester, (αR,γS)-
  • Sacubitril API
  • Sacubtril(LCZ696)
  • LCZ 696
Copyright 2017 © ChemicalBook. All rights reserved